Real-World Analysis of Medical Costs and Healthcare Resource Utilization in Elderly Women with HR+/HER2− Metastatic Breast Cancer Receiving Everolimus-Based Therapy or Chemotherapy

被引:0
作者
Yanni Hao
Nanxin Li
Anna P. Fang
Valerie Koo
Miranda Peeples
Andrew Kageleiry
Eric Q. Wu
Annie Guérin
机构
[1] Novartis Pharmaceuticals Corporation,
[2] Analysis Group,undefined
[3] Inc.,undefined
[4] Analysis Group,undefined
[5] Inc.,undefined
来源
Advances in Therapy | 2016年 / 33卷
关键词
Chemotherapy; Costs; Elderly; Everolimus-based therapy; Healthcare resource utilization; HR+/HER2− metastatic breast cancer; Oncology;
D O I
暂无
中图分类号
学科分类号
摘要
引用
收藏
页码:983 / 997
页数:14
相关论文
共 126 条
[1]  
Wildiers H(2007)Management of breast cancer in elderly individuals: recommendations of the International Society of Geriatric Oncology Lancet Oncol. 8 1101-1115
[2]  
Kunkler I(2009)Breast cancer metastasis: challenges and opportunities Cancer Res 69 4951-4953
[3]  
Biganzoli L(2011)Older women with breast cancer: slow progress, great opportunity, now is the time J Clin Oncol 29 4608-4610
[4]  
Fracheboud J(2012)Association between age at diagnosis and disease-specific mortality among postmenopausal women with hormone receptor-positive breast cancer JAMA. 307 590-597
[5]  
Vlastos G(2015)Treating Elderly patients with hormone receptor-positive advanced breast cancer Clin Med Insights Oncol. 9 65-73
[6]  
Bernard-Marty C(2015)Taxanes in the elderly patient with metastatic breast cancer Breast cancer. 7 293-301
[7]  
Lu J(1999)Underrepresentation of patients 65 years of age or older in cancer-treatment trials N Engl J Med 341 2061-2067
[8]  
Steeg PS(2011)Healthcare costs in women with metastatic breast cancer receiving chemotherapy as their principal treatment modality BMC Cancer 11 250-267
[9]  
Price JE(2011)Anthracycline cardiotoxicity in the elderly cancer patient: a SIOG expert position paper Ann Oncol 22 257-529
[10]  
Krishnamurthy S(2012)Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer New Engl J Med. 366 520-529